Noveome Biotherapeutics, Inc. is a clinical stage company focused on breakthrough therapies for the regenerative repair of inflamed or damaged tissues.

Biotechnology

Noveome Biotherapeutics

Ziv Kirshner has a wealth of experience in the field of biotechnology engineering. Ziv began their career in 2005 when they earned their B.Sc. in Biotechnology Engineering from Ort Braude College of Engineering. In 2008, they held a Molecular Biology Research Internship at the University of Rochester School of Medicine and Dentistry, and a Scientist position at MultiGene Vascular Systems (MGVS) Ltd. In 2011, they began a Doctoral Researcher role at the University of Pittsburgh School of Pharmacy. In 2018, they were a Lead Technology Transfer and Process Scientist III, MSAT, Cell & Gene Therapies at Lonza. Most recently, they have been R&D Director of Advanced Analytical Sciences, a Research and Development Scientist, and a Process Development Scientist at Noveome Biotherapeutics, Inc. since 2019.

Ziv Kirshner began their educational journey in 2005 when they earned a B.Sc in Biotechnology Engineering from Braude Academic College. In 2008 and 2009, they completed a research internship at the University of Rochester. In 2011, they began their Doctor of Philosophy (Ph.D.) in Pharmaceutical Sciences at the University of Pittsburgh, which they completed in 2018. Ziv is also an International Scholar at the International Sephardic Education Foundation (ISEF) since 2006.

Ziv Kirshner

James Cowan has been working in the field of research and development since 2018. James began their career at Eurofins Lancaster Laboratories as a Scientist I in 2018. In 2017, they worked as a Customer Service Cashier at Hannaford Supermarkets. In 2022, they joined Noveome Biotherapeutics, Inc. as a Research and Development Scientist II and also served as a Research and Development Intern.

James Cowan has a diverse educational background. James obtained an Associate of Science degree in Biotechnology from Hudson Valley Community College in 2014-2016. James then went on to obtain a Bachelor's degree in Biochemistry from SUNY New Paltz in 2016-2018. Currently, they are pursuing a Master's degree in Biomedical/Medical Engineering from Carnegie Mellon University, which they are expected to complete in 2021-2022. James is also pursuing a Master of Science degree in Biomedical Engineering from Carnegie Mellon University, which they are expected to complete in 2021-2022.

James Cowan

Shawna Rose has worked in the regulatory affairs field since 2001. Shawna began their career at Alkermes as a Senior Associate in Regulatory Affairs. In 2007, they moved to Biogen as a Sr. Manager in Regulatory Affairs. In 2010, they joined Devicor Medical Products as a Director in Regulatory Affairs. In 2016, they joined Leica Biosystems as a Sr. Director in Quality and Regulatory Affairs. In 2019, they moved to Medpace as a Director in Regulatory Affairs and Head of Regulatory Affairs Operations. Currently, they are a Sr. Regulatory Affairs Director at Noveome Biotherapeutics, Inc.

Shawna Rose attended Butte High School from 1983 to 1985, where they obtained their High School diploma. Shawna then went on to Montana Technological University from 1985 to 1994, where they earned a Bachelor's of Science degree in Science, Technology and Society.

Shawna Rose

Maria Weber has worked in a variety of roles since 1997. Maria began their career as a Senior Auditor at Sisterson & Co. LLP in 1997. In 2000, they moved to H J Heinz Company as a Trade Financial Analyst. In 2008, they joined Stemnion, Inc. as an Accounting Manager. Since 2016, they have been with Noveome Biotherapeutics, Inc., where they have held roles as VP of Administration & Controller and Acting CFO & Controller.

Maria Weber obtained a Bachelor of Science in Accounting and International Business from Duquesne University. Maria also holds a Certified Public Accountant certification.

Maria Weber

Marianne Cascino, MBA has over 25 years of experience in the pharmaceutical and biotechnology industries. Marianne began their career in 1991 as a Project Leader at Schering-Plough. In 2000, they joined sanofi-aventis as a Director of Clinical Operations and a Project Manager of Oncology and Cardiovascular. In 2006, they moved to Roche as a Director of Global Program Management (Clinical Operations). In 2014, they joined Bristol-Myers Squibb as an Associate Director of Late Phase Sponsored Projects. Marianne is currently the Director of Project Management at Noveome Biotherapeutics, Inc.

Marianne Cascino holds an MBA from the University of Phoenix and a Bachelor of Science (BS) in Nursing from Duquesne University. Marianne also has a certification in Project Management.

Marianne Cascino, MBA

Howard Wessel has over 25 years of experience in research and development. From 1993 to 2000, they were a Research Specialist at the University of Pittsburgh, where they conducted molecular cloning, PCR, and radiolabeled hybridization of the Varicella Zoster Virus (VZV) genes, as well as characterization and purification of the human corneal extracellular matrix proteins. Howard also developed monoclonal antibodies to Type XII Collagen and Rho-associated protein kinase. From 2000 to 2007, they worked as a Research Consultant at Generin Diagnostics, developing and validating enzyme assays to diagnose and monitor Gaucher’s patients on Enzyme Replacement Therapy. Howard also managed multiple projects, inventory of materials, shipping, receiving and billing for patient diagnostic kits. From 2007 to 2013, they were the Laboratory Manager at Stemnion. From 2013 to 2017, they were the Research and Development Manager at Noveome Biotherapeutics, Inc., where they were responsible for assay development for product testing and quality control, as well as formulation and product development of biological wound therapies and manufacturing process development and improvement. In 2017, they were promoted to Associate Director of Research and Development at Noveome Biotherapeutics, Inc., where they were involved in development of a novel cell secretome drug product, from source material through manufacturing and testing. Howard also developed secretome drug formulations, tests to monitor protein aggregation and stability of drug products and intermediates, and cell-based assays to assess proliferation, cell attachment and doubling time, cell apoptosis and response to inflammation.

Howard Wessel received their MBA in Health Sciences from Chatham University in 2007, and their B.S. in Life Science/Microbiology from Penn State University in 1993.

Howard Wessel

Gretchen Kraemer

Chad Glyde has a wealth of experience in the quality control field. Chad began their career in 2005 at Boehringer Ingelheim, where they held various roles, including Stability Program Supervisor - Quality Control, Stability Coordinator, and Chemist II. In 2014, they joined Hospira as a Quality Engineer - Marketed Product Quality. In 2016, they joined Noveome Biotherapeutics, Inc., where they held the roles of Director of Quality and Associate Director of Quality Control.

Chad Glyde received their Bachelor's degree in Chemistry from Ohio University between 1999 and 2004.

Chad Glyde

Brandon Biter has worked for five different companies since 2008. Brandon's first position was as an Intern for the Huntingdon County Chamber of Commerce, which they held from 2008 to 2008. Brandon then worked as an Excel & Accounting Tutor at Juniata College from 2008 to 2009. After that, they were an Accountant at Altis Group from 2009 to 2012. Brandon then moved to Triangle Tech, where they held the role of Corporate Accountant from 2012 to 2019. Finally, they have been working at Noveome Biotherapeutics, Inc. since 2019, where they have held the roles of Controller, Accounting Manager, and Senior Accountant.

Brandon Biter obtained a Bachelor of Arts (B.A.) in Accounting from Juniata College between 2005 and 2009. In 2013, they obtained a Quickbooks Accountant Certification from Intuit, Inc.

Brandon Biter

Ashley Ellis

Randall Rupp

Hedvika Davis, PhD

Houman Hemmati is a board-certified ophthalmologist and leader in translational and late-stage drug development. He is presently the Chief Medical Officer of Vyluma, Inc., which is developing a pharmacologic treatment for nearsightedness (myopia). He is also Co-Founder and Chief Scientific Officer of aesthetic medicine company Levation Pharma and retina therapeutics company Optigo Biotherapeutics, which is developing long-acting intravitreal drugs for wet macular degeneration and diabetic eye disease. Additionally, he is on the Board of Directors of Trailhead Biosystems (stem cells) and MediPrint Ophthalmics (contact lens drug delivery) and advises a handful of companies in ophthalmology drug development. He previously served as Director, Clinical Development at Allergan, and as Clinical Scientist in the Ophthalmology Therapeutic Area on several Phase 1, 2, and 3 studies, including the Phase 2 study for the program that led to the approval of Vuity to treat presbyopia.

Houman Hemmati

 Eric Keller is a proven business and legal executive with nearly 30 years of experience in life sciences-based companies. He is the Founder and CEO of Redux Therapeutics, LLC, a clinical-stage small molecule drug development company; Co-Founder and Head of Strategy at C2Sense, an MIT-based medical diagnostic company; Executive Vice President of SGH2 Energy Global, a developer and operator of waste to green hydrogen projects; and Strategic Advisor and Chief Business Officer of SipNose, Ltd., a pioneering Israeli company delivering drugs direct nose-to-brain to treat a variety of CNS and other brain-related disorders.

Eric Keller

Dr. Brown joined Noveome in 2012. Dr. Brown has over 35 years of experience in startup and large pharmaceutical corporations, most recently at Baxter Healthcare Corporation as VP of Research and corporate head of drug delivery.

He has conceived of, researched, and developed numerous novel pharmaceutical formulations and product portfolios and has over 100 publications and key patents in the pharmaceutical biotechnology field. Dr. Brown is a frequent international industry speaker at major pharmaceutical conferences in the fields of drug delivery, diabetes, and advances in biotechnology. 

He obtained his Sc.D. in Biochemistry from the Massachusetts Institute of Technology.

Larry R. Brown

Mr. Welch formed WeGo Consulting, LLC in Loudon, TN in 2014 after almost 27 years with [Allergan](/org/allergan), Inc. 

At [Allergan](/org/allergan), he was Vice President Sales and Marketing for the U.S. Retina Business Unit, and Vice President, Sales, and Marketing for [Allergan](/org/allergan) Medical Dermatology while continuing in his role with U.S. Retina. Outside the U.S., he was Vice President/Managing Director of [Allergan](/org/allergan) Asia Pacific Region for Medical Aesthetics and Neuroscience, as well as President & Managing Director of [Allergan](/org/allergan) Korea. 

Mr. Welch was also U.S. Director of Marketing, Glaucoma, directing the entire Glaucoma portfolio, and managed the pre-approval planning of RESTASIS® and LUMIGAN®. Mr. Welch was also Vice President of the U.S. Managed Healthcare Reimbursement Division and created the initial Government Affairs Operation for [Allergan](/org/allergan).

Patrick T. Welch

Mr. Golden founded the Company in 2000. He has served as either Chairman and CEO or Executive Chairman since inception. 

In 1997, Mr. Golden approached UPMC Health System for assistance in starting an SBA-funded venture capital firm to stimulate the development of a life sciences industry cluster in Pittsburgh. The result was the founding in 1998 of Lancet Capital Health Ventures, L.P., the first SBA-licensed venture capital firm affiliated with an academic medical center. Lancet Capital was the seed investor in Noveome; its limited partners include Pittsburgh’s leading healthcare institutions including UPMC Health System, [Highmark Health](/org/highmark-health), the [University of Pittsburgh](/org/university-of-pittsburgh), and [Carnegie Mellon University](/org/carnegie-mellon-university). Mr. Golden served as Managing Director of Lancet Capital from 1998 to 2021. 

Previously, Mr. Golden spent 5 years as Director of a venture capital fund affiliated with [Boston University](/org/boston-university). 

Mr. Golden has an M.B.A. from [Harvard Business School](/org/harvard-business-school) and a B.S. in Mechanical Engineering from the [University of Notre Dame](/org/university-of-notre-dame). He is a Chartered Financial Analyst.

William J. Golden

Dr. Poropatich is an experienced Pulmonary/Critical Care Medicine physician-scientist who serves as the Director of the Center for Military Medicine Research (CMMR), Health Sciences, and Professor of Medicine in the Division of Pulmonary, Allergy, and Critical Care Medicine at the [University of Pittsburgh](/org/university-of-pittsburgh). The Pitt CMMR has been instrumental in building collaborative multi-disciplinary and multi-organizational research teams to improve the health and well-being of service members, veterans, and their families that have led to significant DoD medical research collaboration with Pitt. Dr. Poropatich has also been on the faculty at the Uniformed Services University of the Health Science (USUHS) since 1985 and currently serves as an Adjunct Professor of Medicine. 

Dr. Poropatich served 30 years on active duty in the U.S. Army retiring in 2012 at the rank of Colonel with extended assignments at the Walter Reed National Military Medical Center (1985 to 2012) and the US Army Medical Research and Development Command (2006-2012).

Ronald K. Poropatich

Dr. Langer has been a member of Noveome’s Board of Directors for over 10 years. He is one of only 12 Institute Professors (MIT’s highest honor). He has written 1,500 articles and has approximately 1350 issued and pending patents. His patents have been licensed or sublicensed to over 400 companies. 

Dr. Langer has received over 220 major awards including the United States National Medal of Science and the United States National Medal of Technology and Innovation (he is one of 4 living individuals to have received both these honors), the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering and Priestley Medal (highest award of the American Chemical Society.) 

He holds 34 honorary doctorates and has been elected to the National Academy of Medicine, the National Academy of Engineering, the [National Academy of Sciences](/org/national-academy-of-sciences) and the [National Academy of Inventors](/org/national-academy-of-inventors).

Robert S. Langer

Noveome Biotherapeutics' Board of Directors includes William J. Golden and 4 others.

Board of Directors

About

Team members

Other teams at Noveome Biotherapeutics

Leadership Team

CEO and Executive Team

Discover similar companies